CURRENT VIEWS ON THE ETIOPATHOGENESIS AND RISK FACTORS OF UTERINE LEIOMYOMA


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The paper carries out a systems analysis of the data available in the current literature on the etiopathogenesis and risk factors of uterine leiomyoma. It gives main etiological hypotheses for uterine leiomyoma, molecular mechanisms for its development, and risk factors for tumor development. According to the current concepts, uterine leiomyoma is a multifactorial andpolyetiological disease, the development of which involves genetic and epigenetic mechanisms, hormone-dependent and hormone- independent myometrial smooth muscle cell proliferation that is determined by growth factors, apoptotic mechanisms, and reactions to injury and inflammation.

Texto integral

Acesso é fechado

Sobre autores

Irina Ponomarenko

Belgorod State National Research University

Email: ponomarenko_i@bsu.edu.ru
MD, associate professor of the Department of Biomedical Disciplines of the Medical Institute 308015, Russia, Belgorod, Pobedy str. 85

Mikhail Churnosov

Belgorod State National Research University

Email: churnosov@bsu.edu.ru
MD, Professor, Head of the Department of Biomedical Disciplines Medical Faculty 308015, Russia, Belgorod, Pobedy str. 85

Bibliografia

  1. Адамян Л.В., ред. Миома матки: диагностика, лечение и реабилитация. Клинические рекомендации по ведению больных. М.: Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова; 2015. 100с.
  2. McWilliams M.M., Chennathukuzhi V.M. Recent advances in uterine fibroid etiology. Semin. Reprod. Med. 2017; 35(2): 181-9.
  3. Carranza-Mamane B., Havelock J., Hemming R. The management of uterine fibroids in women with otherwise unexplained infertility. J. Obstet. Gynaecol. Can. 2015; 37(3): 277-85.
  4. Segars J.H., Parrott E.C., Nagel J.D., Guo X.C., Gao X., Birnbaum L.S. et al. Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations. Hum. Reprod. Update. 2014; 20(3): 309-33.
  5. Cardozo E.R., Clark A.D., Banks N.K., Henne M.B., Stegmann B.J., Segars J.H. The estimated annual cost of uterine leiomyomata in the United States. Am. J. Obstet. Gynecol. 2012; 206(3): 211. e1-211. e9.
  6. Sparic R., Mirkovic L., Malvasi A., Tinelli A. Epidemiology of uterine myomas: a review. Int. J. Fertil. Steril. 2016; 9(4): 424-35.
  7. Wise L.A., Laughlin-Tommaso S.K. Epidemiology of uterine fibroids - from menarche to menopause. Clin. Obstet. Gynecol. 2016; 59(1): 2-24.
  8. Navarro A., Yin P., Monsivais D., Lin S.M., Du P., Wei J.-J., Bulun S.E. Genome-wide DNA methylation indicates silencing of tumor suppressor genes in uterine leiomyoma. PLoS One. 2012; 7(3): e33284.
  9. Maekawa R., Sato S., Yamagata Y., Asada H., Tamura I., Lee L. et al. Genome-wide DNA methylation analysis reveals a potential mechanism for the pathogenesis and development of uterine leiomyomas. PLoS One. 2013; 8(6): e66632.
  10. Manta L., Suciu N., Toader O., Purcärea R., Constantin A., Popa F. The etiopathogenesis of uterine fibromatosis. J. Med. Life. 2016; 9(1): 39-45.
  11. Moravek M.B., Yin P., Ono M., Coon J.S., Dyson M.T., Navarro A. et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum. Reprod. Update. 2015; 21(1): 1-12.
  12. Киселев В.И., Сидорова И.С., Унанян А.Л., Муйжнек Е.Л. Гиперпластические процессы органов женской репродуктивной системы: теория и практика. М.: МЕДПРАКТИКА-М; 2010. 468с.
  13. Katz T.A., Yang Q., Trevino L.S., Walker C.L., Al-Hendy A. Endocrine disrupting chemicals and uterine fibroids. Fertil. Steril. 2016; 106(4): 967-77.
  14. Тихомиров А.Л., ред. Миома, патогенетическое обоснование органосохраняющего лечения. М.; 2013. 319с.
  15. Сидорова И.С., Унанян А.Л., Агеев М.Б., Ведерникова Н.В., Жолобова М.Н. Современное состояние вопроса о патогенезе, клинике, диагностике и лечении миомы матки у женщин репродуктивного возраста. Акушерство, гинекология и репродукция. 2012; 4: 22-8.
  16. Ciavattini A., Di Giuseppe J., Stortoni P., Montik N., Giannubilo S.R., Litta P. et al. Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction. Obstet. Gynecol. Int. 2013; 2013: 173184.
  17. Ciavattini A., Delli Carpini G., Serri M., Vignini A., Sabbatinelli J., Tozzi A. et al. Hypovitaminosis D and “small burden” uterine fibroids: Opportunity for a vitamin D supplementation. Medicine (Baltimore). 2016; 95(52): e5698.
  18. Brakta S., Diamond J.S., Al-Hendy A., Diamond M.P, Haider S.K. The role of vitamin D in uterine fibroid biology. Fertil. Steril. 2015; 104(3): 698-706.
  19. Радзинский В.Е., Архипова М.П. Миома матки: проблемы и перспективы начала века. Медицинский совет. 2014. 9: 30-3. [Radzinsky V.E., Arkhipova M.P. Uterine fibroids: problems and prospects of the beginning of the century. Medical advice. 2014. 9: 30-3. (in Russian)]
  20. Khan A.T., Shehmar M., Gupta J.K. Uterine fibroids: current perspectives. Int. J. Women’s Health. 2014; 6: 95-114.
  21. Catherine W.H., Eltoukhi H.M., Al-Hendy A. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin. Reprod. Med. 2013; 31(5): 370-9.
  22. Tak Y.J., Lee S.Y., Park S.K., Kim Y.J., Lee J.G., Jeong D.W et al. Association between uterine leiomyoma and metabolic syndrome in parous premenopausal women: a case-control study. Medicine (Baltimore). 2016; 95(46): e5325.
  23. Yang Y., He Y., Zeng Q., Li S. Association of body size and body fat distribution with uterine fibroids among Chinese women. J. Womens Health. 2014; 23(7): 619-26.
  24. Dragomir A.D., Schroeder J.C., Connolly A., Kupper L.L., Hill M.C., Olshan A.F. et al. Potential risk factors associated with subtypes of uterine leiomyomata. Reprod. Sci. 2010; 17(11): 1029-35.
  25. Velez Edwards D.R., Baird D.D., Hartmann K.E. Association of age at menarche with increasing number of fibroids in a cohort of women who underwent standardized ultrasound assessment. Am. J. Epidemiol. 2013; 178(3): 426-33.
  26. Zimmermann A., Bernuit D., Gerlinger C., Schaefers M., Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Women’s Health. 2012; 12: 6.
  27. Shen Q., Shu L., Luo H., Hu X., Zhu X. The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas. Medicine (Baltimore). 2017; 96(17): e6680.
  28. Song L., Shen L., Mandiwa C., Yang S., Liang Y., Yuan J., Wang Y. Induced and spontaneous abortion and risk of uterine fibroids. J. Womens Health. 2017; 26(1): 76-82.
  29. Sedgh G., Singh S., Shah I.H., Ähman E., Henshaw S.K., Bankole A. Induced abortion: incidence and trends worldwide from 1995 to 2008. Lancet. 2012; 379(9816): 625-32.
  30. Denisov B.P, Sakevich V.I., Jasilioniene A. Divergent trends in abortion and birth control practices in Belarus, Russia and Ukraine. PLoS One. 2012; 7(11): e49986.
  31. Douglas N.I., Pavlova T.U., Burtseva T.E., Rad Y.G., Petrova P.G., Odland J.Ø. Women’s reproductive health in the Sakha Republic (Yakutia). Int. J. Circumpolar Health. 2014; 73: 10.
  32. He Y., Zeng Q., Li X., Liu B., Wang P. The association between subclinical atherosclerosis and uterine fibroids. PLoS One. 2013; 8(2): e57089.
  33. Wise L.A., Laughlin-Tommaso S.K. Uterine leiomyomata. In: Goldman M.B., Troisi R., Rexrode K.M., eds. Women and health. San Diego: Academic Press; 2013: 285-306.
  34. Radin R.G., Rosenberg L., Palmer J.R., Cozier Y.C., Kumanyika S.K., Wise L.A. Hypertension and risk of uterine leiomyomata in US black women. Hum. Reprod. 2012; 27(5): 1504-9.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2018